Joshua Aaron Lees
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Joshua Aaron Lees has a total of 51 co-authors. Here are the top co-authors by number of shared publications:
Karin M Reinisch
Department of Cell Biology, Yale University School of Medicine, USA
4 shared publications- Karin M. Reinisch
Department of Cell Biology, Yale University School of Medicine, New Haven, CT, USA
4 shared publications - Nikit Kumar
Department of Cell Biology, Yale University School of Medicine, New Haven, CT
2 shared publications - PeiQi Li
Department of Cell Biology, Yale School of Medicine
2 shared publications - Pietro De Camilli
Department of Neuroscience, Yale University School of Medicine, New Haven, USA
2 shared publications - Seungil Han
Discovery Sciences, Medicine Design, Pfizer Inc., Groton, USA
2 shared publications
Latest Publications
- Open Access
- 7 April 2025
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 301  (5) , 108484
Cyclosporine A sterically inhibits statin transport by solute carrier OATP1B1
- 7 April 2025
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 301  (5) , 108484
Open AccessCyclosporine A sterically inhibits statin transport by solute carrier OATP1B1
- Top Cited Papers
- 26 April 2023
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 15  (693) , eade6422
Rational design of a highly immunogenic prefusion-stabilized F glycoprotein antigen for a respiratory syncytial virus vaccine
Respiratory syncytial virus (RSV) is the leading, global cause of serious respiratory disease in infants and is an important cause of respiratory illness in older adults. No RSV vaccine is currently available. The RSV fusion (F) glycoprotein is a key antigen for vaccine development, and its prefusion conformation is the target of the most potent neutralizing antibodies. Here, we describe a computational and experimental strategy for designing immunogens that enhance the conformational stability and immunogenicity of RSV prefusion F. We obtained an optimized vaccine antigen after screening nearly 400 engineered F constructs. Through in vitro and in vivo characterization studies, we identified F constructs that are more stable in the prefusion conformation and elicit ~10-fold higher serum-neutralizing titers in cotton rats than DS-Cav1. The stabilizing mutations of the lead construct (847) were introduced onto F glycoprotein backbones of strains representing the dominant circulating genotypes of the two major RSV subgroups, A and B. Immunization of cotton rats with a bivalent vaccine formulation of these antigens conferred complete protection against RSV challenge, with no evidence of disease enhancement. The resulting bivalent RSV prefusion F investigational vaccine has recently been shown to be efficacious against RSV disease in two pivotal phase 3 efficacy trials, one for passive protection of infants by immunization of pregnant women and the second for active protection of older adults by direct immunization.
- 26 April 2023
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 15  (693) , eade6422
Top Cited PapersRational design of a highly immunogenic prefusion-stabilized F glycoprotein antigen for a respiratory syncytial virus vaccine
Respiratory syncytial virus (RSV) is the leading, global cause of serious respiratory disease in infants and is an important cause of respiratory illness in older adults. No RSV vaccine is currently available. The RSV fusion (F) glycoprotein is a key antigen for vaccine development, and its prefusion conformation is the target of the most potent neutralizing antibodies. Here, we describe a computational and experimental strategy for designing immunogens that enhance the conformational stability and immunogenicity of RSV prefusion F. We obtained an optimized vaccine antigen after screening nearly 400 engineered F constructs. Through in vitro and in vivo characterization studies, we identified F constructs that are more stable in the prefusion conformation and elicit ~10-fold higher serum-neutralizing titers in cotton rats than DS-Cav1. The stabilizing mutations of the lead construct (847) were introduced onto F glycoprotein backbones of strains representing the dominant circulating genotypes of the two major RSV subgroups, A and B. Immunization of cotton rats with a bivalent vaccine formulation of these antigens conferred complete protection against RSV challenge, with no evidence of disease enhancement. The resulting bivalent RSV prefusion F investigational vaccine has recently been shown to be efficacious against RSV disease in two pivotal phase 3 efficacy trials, one for passive protection of infants by immunization of pregnant women and the second for active protection of older adults by direct immunization.
- Top Cited PapersOpen Access
- 17 March 2020
- Published by Rockefeller University Press in Journal of Cell Biology
- Vol. 219  (5)
Cryo-EM reconstruction of a VPS13 fragment reveals a long groove to channel lipids between membranes
A single particle cryo-EM reconstruction of an ∼160-kD N-terminal fragment of the lipid transport protein VPS13 reveals an ∼160-Å long channel lined with hydrophobic residues suitable for solubilizing multiple lipid fatty acid moieties. The structure suggests that VPS13 and related proteins, like the autophagy protein ATG2, can act as bridges between organelle membranes to allow bulk lipid flow between organelles.
- 17 March 2020
- Published by Rockefeller University Press in Journal of Cell Biology
- Vol. 219  (5)
Top Cited PapersOpen AccessCryo-EM reconstruction of a VPS13 fragment reveals a long groove to channel lipids between membranes
A single particle cryo-EM reconstruction of an ∼160-kD N-terminal fragment of the lipid transport protein VPS13 reveals an ∼160-Å long channel lined with hydrophobic residues suitable for solubilizing multiple lipid fatty acid moieties. The structure suggests that VPS13 and related proteins, like the autophagy protein ATG2, can act as bridges between organelle membranes to allow bulk lipid flow between organelles.
- Top Cited PapersOpen Access
- 5 April 2019
- Published by Rockefeller University Press in Journal of Cell Biology
- Vol. 218  (6) , 1787-1798
ATG2 transports lipids to promote autophagosome biogenesis
During macroautophagic stress, autophagosomes can be produced continuously and in high numbers. Many different organelles have been reported as potential donor membranes for this sustained autophagosome growth, but specific machinery to support the delivery of lipid to the growing autophagosome membrane has remained unknown. Here we show that the autophagy protein, ATG2, without a clear function since its discovery over 20 yr ago, is in fact a lipid-transfer protein likely operating at the ER–autophagosome interface. ATG2A can bind tens of glycerophospholipids at once and transfers lipids robustly in vitro. An N-terminal fragment of ATG2A that supports lipid transfer in vitro is both necessary and fully sufficient to rescue blocked autophagosome biogenesis in ATG2A/ATG2B KO cells, implying that regulation of lipid homeostasis is the major autophagy-dependent activity of this protein and, by extension, that protein-mediated lipid transfer across contact sites is a principal contributor to autophagosome formation.
- 5 April 2019
- Published by Rockefeller University Press in Journal of Cell Biology
- Vol. 218  (6) , 1787-1798
Top Cited PapersOpen AccessATG2 transports lipids to promote autophagosome biogenesis
During macroautophagic stress, autophagosomes can be produced continuously and in high numbers. Many different organelles have been reported as potential donor membranes for this sustained autophagosome growth, but specific machinery to support the delivery of lipid to the growing autophagosome membrane has remained unknown. Here we show that the autophagy protein, ATG2, without a clear function since its discovery over 20 yr ago, is in fact a lipid-transfer protein likely operating at the ER–autophagosome interface. ATG2A can bind tens of glycerophospholipids at once and transfers lipids robustly in vitro. An N-terminal fragment of ATG2A that supports lipid transfer in vitro is both necessary and fully sufficient to rescue blocked autophagosome biogenesis in ATG2A/ATG2B KO cells, implying that regulation of lipid homeostasis is the major autophagy-dependent activity of this protein and, by extension, that protein-mediated lipid transfer across contact sites is a principal contributor to autophagosome formation.
- Top Cited PapersOpen Access
- 9 August 2018
- Published by Rockefeller University Press in Journal of Cell Biology
- Vol. 217  (10) , 3625-3639
VPS13A and VPS13C are lipid transport proteins differentially localized at ER contact sites
Mutations in the human VPS13 genes are responsible for neurodevelopmental and neurodegenerative disorders including chorea acanthocytosis (VPS13A) and Parkinson’s disease (VPS13C). The mechanisms of these diseases are unknown. Genetic studies in yeast hinted that Vps13 may have a role in lipid exchange between organelles. In this study, we show that the N-terminal portion of VPS13 is tubular, with a hydrophobic cavity that can solubilize and transport glycerolipids between membranes. We also show that human VPS13A and VPS13C bind to the ER, tethering it to mitochondria (VPS13A), to late endosome/lysosomes (VPS13C), and to lipid droplets (both VPS13A and VPS13C). These findings identify VPS13 as a lipid transporter between the ER and other organelles, implicating defects in membrane lipid homeostasis in neurological disorders resulting from their mutations. Sequence and secondary structure similarity between the N-terminal portions of Vps13 and other proteins such as the autophagy protein ATG2 suggest lipid transport roles for these proteins as well.
- 9 August 2018
- Published by Rockefeller University Press in Journal of Cell Biology
- Vol. 217  (10) , 3625-3639
Top Cited PapersOpen AccessVPS13A and VPS13C are lipid transport proteins differentially localized at ER contact sites
Mutations in the human VPS13 genes are responsible for neurodevelopmental and neurodegenerative disorders including chorea acanthocytosis (VPS13A) and Parkinson’s disease (VPS13C). The mechanisms of these diseases are unknown. Genetic studies in yeast hinted that Vps13 may have a role in lipid exchange between organelles. In this study, we show that the N-terminal portion of VPS13 is tubular, with a hydrophobic cavity that can solubilize and transport glycerolipids between membranes. We also show that human VPS13A and VPS13C bind to the ER, tethering it to mitochondria (VPS13A), to late endosome/lysosomes (VPS13C), and to lipid droplets (both VPS13A and VPS13C). These findings identify VPS13 as a lipid transporter between the ER and other organelles, implicating defects in membrane lipid homeostasis in neurological disorders resulting from their mutations. Sequence and secondary structure similarity between the N-terminal portions of Vps13 and other proteins such as the autophagy protein ATG2 suggest lipid transport roles for these proteins as well.
- 17 February 2017
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 355  (6326)
Lipid transport by TMEM24 at ER–plasma membrane contacts regulates pulsatile insulin secretion
Understanding insulin release: Insulin release takes place in two phases: a first rapid burst followed by a series of small exocytic bursts that coincide with pulsatile spikes in cytosolic Ca 2+ levels. The second phase is impaired in patients with type II diabetes, underscoring the importance of understanding its molecular basis. Lees et al. report a mechanism through which TMEM24, a lipid transport protein that concentrates at endoplasmic reticulum–plasma membrane contact sites, regulates the pulsatility of cytosolic Ca 2+ and phosphoinositide signaling. This process in turn regulates pulsatile insulin secretion during the slow insulin release phase. Science , this issue p. eaah6171
- 17 February 2017
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 355  (6326)
Lipid transport by TMEM24 at ER–plasma membrane contacts regulates pulsatile insulin secretion
Understanding insulin release: Insulin release takes place in two phases: a first rapid burst followed by a series of small exocytic bursts that coincide with pulsatile spikes in cytosolic Ca 2+ levels. The second phase is impaired in patients with type II diabetes, underscoring the importance of understanding its molecular basis. Lees et al. report a mechanism through which TMEM24, a lipid transport protein that concentrates at endoplasmic reticulum–plasma membrane contact sites, regulates the pulsatility of cytosolic Ca 2+ and phosphoinositide signaling. This process in turn regulates pulsatile insulin secretion during the slow insulin release phase. Science , this issue p. eaah6171
- 10 August 2016
- Published by H1 Connect
- Vol. 23  (8)
Faculty Opinions recommendation of Molecular architecture of the complete COG tethering complex.
The conserved oligomeric Golgi (COG) complex is a multi-subunit tethering complex (MTC) of the so-called CATCHR family. Its interactions with members of most other protein families involved in vesicle trafficking, including SNAREs, coat proteins, SM proteins, and Rab GTPases suggest a coordinating role in vesicle fusion at the Golgi membrane. Crystal structures of individual CATCHR complex subunits have revealed similar folds, suggesting...
- 10 August 2016
- Published by H1 Connect
- Vol. 23  (8)
Faculty Opinions recommendation of Molecular architecture of the complete COG tethering complex.
The conserved oligomeric Golgi (COG) complex is a multi-subunit tethering complex (MTC) of the so-called CATCHR family. Its interactions with members of most other protein families involved in vesicle trafficking, including SNAREs, coat proteins, SM proteins, and Rab GTPases suggest a coordinating role in vesicle fusion at the Golgi membrane. Crystal structures of individual CATCHR complex subunits have revealed similar folds, suggesting...
- 5 July 2016
- Published by H1 Connect
Faculty Opinions recommendation of Structural basis of intramitochondrial phosphatidic acid transport mediated by Ups1-Mdm35 complex.
Ups1 is a soluble MSF1/PRELI-family mitochondrial phosphatidic acid (PA) transporter required for cardiolipin synthesis in the inner mitochondrial membrane (IMM). Mdm35, a mitochondrial intermembrane space (IMS)-resident protein, is required for the import and maintenance of functional Ups1 in the IMS, but the mechanisms of this dependency and of lipid transfer by the complex were unknown. Yu et al. and Watanabe et al. {1} independently reported structures of the Ups1/Mdm35 complex. Strikingly, unlike other START-related proteins, which comprise a single polypeptide, Ups1 and Mdm35 cooperate to form a functional START domain. This feature is key to the regulation of PA transport activity in the IMS and sheds new light on the diverse regulatory mechanisms governing the growing family of non-vesicular lipid transfer proteins. In each crystal structure, Ups1 lacks an N-terminal helix that in other START domain proteins packs against the protein surface. Mdm35, a small protein of only 86 residues, binds a similar face of Ups1 and may function partly as a substitute for this bracing helix. Both groups found that this interaction stabilizes Ups1 and likely ensures that Ups1 is functional only in the mitochondrial IMS, restricting its PA transfer activity to this compartment. Both groups identified several key features that provide insights into PA binding and transfer by Ups1/Mdm35. PA binds head-first within a Ups1 cavity lined with hydrophobic residues, but with a key hydrophilic residue (Arg25) deep within the cavity that positions the head group. Like other START-domain proteins, Ups1 contains a lid structure at the opening of the cavity required for complex activity both in vitro and in vivo. Intriguingly, the lid exhibits high temperature factors and adopts different conformations in the Yu and Watanabe structures, suggesting a possible conformational change required for lipid extraction. Finally, a hydrophilic patch on the surface of Ups1 near the opening of the PA binding cavity is required for CL-specific membrane binding of the complex, as well as PA binding and transfer. In vivo, Ups1 binding to CL in the IMM is thought both to recruit it to deliver PA and, under high CL conditions, to sequester it on the IMM to prevent further PA transfer, serving to regulate its activity. In a further insight, Watanabe et al. discovered that transient Mdm35 dissociation is required for Ups1 activity {1}. Using different strategies to tether the proteins together, they found that PA transfer occurs only when binding between Ups1 and Mdm35 is reversible. Though not reviewed here, another important paper, published alongside Yu et al., describes the structure of the TRIAP1-SLMO1 complex, another member of the PRELI protein family {2}. Together, these represent the first known structures of PRELI family proteins and make an important new contribution to our understanding of the large (and expanding) family of lipid transfer proteins.
- 5 July 2016
- Published by H1 Connect
Faculty Opinions recommendation of Structural basis of intramitochondrial phosphatidic acid transport mediated by Ups1-Mdm35 complex.
Ups1 is a soluble MSF1/PRELI-family mitochondrial phosphatidic acid (PA) transporter required for cardiolipin synthesis in the inner mitochondrial membrane (IMM). Mdm35, a mitochondrial intermembrane space (IMS)-resident protein, is required for the import and maintenance of functional Ups1 in the IMS, but the mechanisms of this dependency and of lipid transfer by the complex were unknown. Yu et al. and Watanabe et al. {1} independently reported structures of the Ups1/Mdm35 complex. Strikingly, unlike other START-related proteins, which comprise a single polypeptide, Ups1 and Mdm35 cooperate to form a functional START domain. This feature is key to the regulation of PA transport activity in the IMS and sheds new light on the diverse regulatory mechanisms governing the growing family of non-vesicular lipid transfer proteins. In each crystal structure, Ups1 lacks an N-terminal helix that in other START domain proteins packs against the protein surface. Mdm35, a small protein of only 86 residues, binds a similar face of Ups1 and may function partly as a substitute for this bracing helix. Both groups found that this interaction stabilizes Ups1 and likely ensures that Ups1 is functional only in the mitochondrial IMS, restricting its PA transfer activity to this compartment. Both groups identified several key features that provide insights into PA binding and transfer by Ups1/Mdm35. PA binds head-first within a Ups1 cavity lined with hydrophobic residues, but with a key hydrophilic residue (Arg25) deep within the cavity that positions the head group. Like other START-domain proteins, Ups1 contains a lid structure at the opening of the cavity required for complex activity both in vitro and in vivo. Intriguingly, the lid exhibits high temperature factors and adopts different conformations in the Yu and Watanabe structures, suggesting a possible conformational change required for lipid extraction. Finally, a hydrophilic patch on the surface of Ups1 near the opening of the PA binding cavity is required for CL-specific membrane binding of the complex, as well as PA binding and transfer. In vivo, Ups1 binding to CL in the IMM is thought both to recruit it to deliver PA and, under high CL conditions, to sequester it on the IMM to prevent further PA transfer, serving to regulate its activity. In a further insight, Watanabe et al. discovered that transient Mdm35 dissociation is required for Ups1 activity {1}. Using different strategies to tether the proteins together, they found that PA transfer occurs only when binding between Ups1 and Mdm35 is reversible. Though not reviewed here, another important paper, published alongside Yu et al., describes the structure of the TRIAP1-SLMO1 complex, another member of the PRELI protein family {2}. Together, these represent the first known structures of PRELI family proteins and make an important new contribution to our understanding of the large (and expanding) family of lipid transfer proteins.
- 28 June 2016
- Published by H1 Connect
Faculty Opinions recommendation of Structural and mechanistic insights into phospholipid transfer by Ups1-Mdm35 in mitochondria.
Ups1 is a soluble MSF1/PRELI-family mitochondrial phosphatidic acid (PA) transporter required for cardiolipin synthesis in the inner mitochondrial membrane (IMM). Mdm35, a mitochondrial intermembrane space (IMS)-resident protein, is required for the import and maintenance of functional Ups1 in the IMS, but the mechanisms of this dependency and of lipid transfer by the complex were unknown. Yu et al. {1} and Watanabe et al. independently reported structures of the Ups1/Mdm35 complex. Strikingly, unlike other START-related proteins, which comprise a single polypeptide, Ups1 and Mdm35 cooperate to form a functional START domain. This feature is key to the regulation of PA transport activity in the IMS and sheds new light on the diverse regulatory mechanisms governing the growing family of non-vesicular lipid transfer proteins. In each crystal structure, Ups1 lacks an N-terminal helix that in other START domain proteins packs against the protein surface. Mdm35, a small protein of only 86 residues, binds a similar face of Ups1 and may function partly as a substitute for this bracing helix. Both groups found that this interaction stabilizes Ups1 and likely ensures that Ups1 is functional only in the mitochondrial IMS, restricting its PA transfer activity to this compartment. Both groups identified several key features that provide insights into PA binding and transfer by Ups1/Mdm35. PA binds head-first within a Ups1 cavity lined with hydrophobic residues, but with a key hydrophilic residue (Arg25) deep within the cavity that positions the head group. Like other START-domain proteins, Ups1 contains a lid structure at the opening of the cavity required for complex activity both in vitro and in vivo. Intriguingly, the lid exhibits high temperature factors and adopts different conformations in the Yu and Watanabe structures, suggesting a possible conformational change required for lipid extraction. Finally, a hydrophilic patch on the surface of Ups1 near the opening of the PA binding cavity is required for CL-specific membrane binding of the complex, as well as PA binding and transfer. In vivo, Ups1 binding to CL in the IMM is thought both to recruit it to deliver PA and, under high CL conditions, to sequester it on the IMM to prevent further PA transfer, serving to regulate its activity. In a further insight, Watanabe et al. discovered that transient Mdm35 dissociation is required for Ups1 activity. Using different strategies to tether the proteins together, they found that PA transfer occurs only when binding between Ups1 and Mdm35 is reversible. Though not reviewed here, another important paper, published alongside Yu et al., describes the structure of the TRIAP1-SLMO1 complex, another member of the PRELI protein family {2}. Together, these represent the first known structures of PRELI family proteins and make an important new contribution to our understanding of the large (and expanding) family of lipid transfer proteins.
- 28 June 2016
- Published by H1 Connect
Faculty Opinions recommendation of Structural and mechanistic insights into phospholipid transfer by Ups1-Mdm35 in mitochondria.
Ups1 is a soluble MSF1/PRELI-family mitochondrial phosphatidic acid (PA) transporter required for cardiolipin synthesis in the inner mitochondrial membrane (IMM). Mdm35, a mitochondrial intermembrane space (IMS)-resident protein, is required for the import and maintenance of functional Ups1 in the IMS, but the mechanisms of this dependency and of lipid transfer by the complex were unknown. Yu et al. {1} and Watanabe et al. independently reported structures of the Ups1/Mdm35 complex. Strikingly, unlike other START-related proteins, which comprise a single polypeptide, Ups1 and Mdm35 cooperate to form a functional START domain. This feature is key to the regulation of PA transport activity in the IMS and sheds new light on the diverse regulatory mechanisms governing the growing family of non-vesicular lipid transfer proteins. In each crystal structure, Ups1 lacks an N-terminal helix that in other START domain proteins packs against the protein surface. Mdm35, a small protein of only 86 residues, binds a similar face of Ups1 and may function partly as a substitute for this bracing helix. Both groups found that this interaction stabilizes Ups1 and likely ensures that Ups1 is functional only in the mitochondrial IMS, restricting its PA transfer activity to this compartment. Both groups identified several key features that provide insights into PA binding and transfer by Ups1/Mdm35. PA binds head-first within a Ups1 cavity lined with hydrophobic residues, but with a key hydrophilic residue (Arg25) deep within the cavity that positions the head group. Like other START-domain proteins, Ups1 contains a lid structure at the opening of the cavity required for complex activity both in vitro and in vivo. Intriguingly, the lid exhibits high temperature factors and adopts different conformations in the Yu and Watanabe structures, suggesting a possible conformational change required for lipid extraction. Finally, a hydrophilic patch on the surface of Ups1 near the opening of the PA binding cavity is required for CL-specific membrane binding of the complex, as well as PA binding and transfer. In vivo, Ups1 binding to CL in the IMM is thought both to recruit it to deliver PA and, under high CL conditions, to sequester it on the IMM to prevent further PA transfer, serving to regulate its activity. In a further insight, Watanabe et al. discovered that transient Mdm35 dissociation is required for Ups1 activity. Using different strategies to tether the proteins together, they found that PA transfer occurs only when binding between Ups1 and Mdm35 is reversible. Though not reviewed here, another important paper, published alongside Yu et al., describes the structure of the TRIAP1-SLMO1 complex, another member of the PRELI protein family {2}. Together, these represent the first known structures of PRELI family proteins and make an important new contribution to our understanding of the large (and expanding) family of lipid transfer proteins.
- 11 November 2014
- Published by H1 Connect
Faculty Opinions recommendation of Structural basis for membrane binding and remodeling by the exomer secretory vesicle cargo adaptor.
This paper from Paczkowski and Fromme reports the structure of the exomer complex bound to the small GTPase Arf1. Exomer is a coat protein-like complex which sorts trans-Golgi network (TGN) cargoes into secretory vesicles bound for the plasma membrane in polarized cells. The studies presented here provide important new insights into this complex whose mechanistic details have thus far been less well understood than for more traditional coat complexes, like clathrin, COPI and COPII. The authors build, in this paper, on the lab's prior structural work with the exomer complex {1,2}, in which they characterized the interactions between the core subunit, Chs5, and the ChAPs (Chs5 and Arf1 binding proteins) family members Bch1 and Chs6, and established that the Chs5 dimer forms an N-terminal flexible hinge that would potentially allow the complex to adapt to variable cargo protein sizes and membrane curvatures. The authors had also previously demonstrated that recruitment of exomer to the membrane depends on additive contributions from Arf1-GTP, which inserts into the membrane via an N-terminal amphipathic helix, and members of the ChAP family. The structure reported in this paper demonstrates that exomer interacts with Arf1-GTP via interaction surfaces on both the Chs5 and ChAP subunits. While Bch1 contacts the switch II region of Arf1 in a nucleotide-sensitive interaction reminiscent of other Arf effectors, the FBE domain of Chs5 interacts via a novel non-canonical interface near the Arf1 nucleotide binding pocket. The authors disrupt these interactions by mutating a single residue in the Arf1 exomer-binding loop and demonstrate both in vitro and in vivo that exomer is no longer recruited to membranes and that trafficking of its model cargo Chs3 is impaired. The quaternary structure of the complex, which comprises two copies of each protein, also reveals the orientation of the exomer complex with respect to the membrane. Its two Bch1 subunits and two copies of Arf1-GTP directly contact the membrane, while the hinge region of the Chs5 dimer is oriented toward the cytosol. Intriguingly, the authors show that the different ChAP family members exhibit different affinities toward membranes, with Chs5/Bch1 requiring Arf1-GTP for membrane recruitment, but Chs5/Chs6 binding independently of Arf1. A conserved basic patch on the surface of Chs6, analogous to the membrane proximal surface of Bch1, is demonstrated through mutation to be essential for membrane binding. The authors further demonstrate, through mutation of inter-subunit binding interfaces, that exomer's membrane recruitment and its trafficking function depend on its network of interactions between subunits and with the membrane. Most striking, however, is the authors' demonstration that exomer can cooperate with Arf1 to remodel membranes in vitro. They employ a vesiculation assay to monitor changes in liposome size due to vesicle fission in the presence of exomer. While Arf1 alone is shown to be capable of inducing vesiculation in the presence of GTP, the authors demonstrate that addition of Chs5/Bch1 complex dramatically strengthens this effect, with a strong preference for a TGN-like membrane composition. Addition of Chs5/Chs6 complex, however, has no such effect. Comparing the membrane binding interfaces of Bch1 and Chs6, the authors identify a hydrophobic patch on the Bch1 surface which is absent in Chs6. Mutating this hydrophobic patch to alanine has no effect on membrane recruitment of exomer, but abrogates Bch1-mediated stimulation of membrane remodeling. This suggests that the hydrophobic patch may act as a "wedge"-like membrane insertion element that cooperates with Arf1 to induce membrane curvature. The flexible hinge of the Chs5 dimer likely allows the dynamic positioning of the membrane insertion elements of both Bch1 and Arf1 during membrane remodeling to accommodate the changing curvature of the membrane. This paper offers direct evidence that the exomer complex can participate in membrane remodeling and provides crucial insights into the mechanism by which exomer, cooperating with Arf1, can induce membrane curvature. These insights hint at a broader repertoire of membrane remodeling proteins distinct from traditional coat proteins.
- 11 November 2014
- Published by H1 Connect
Faculty Opinions recommendation of Structural basis for membrane binding and remodeling by the exomer secretory vesicle cargo adaptor.
This paper from Paczkowski and Fromme reports the structure of the exomer complex bound to the small GTPase Arf1. Exomer is a coat protein-like complex which sorts trans-Golgi network (TGN) cargoes into secretory vesicles bound for the plasma membrane in polarized cells. The studies presented here provide important new insights into this complex whose mechanistic details have thus far been less well understood than for more traditional coat complexes, like clathrin, COPI and COPII. The authors build, in this paper, on the lab's prior structural work with the exomer complex {1,2}, in which they characterized the interactions between the core subunit, Chs5, and the ChAPs (Chs5 and Arf1 binding proteins) family members Bch1 and Chs6, and established that the Chs5 dimer forms an N-terminal flexible hinge that would potentially allow the complex to adapt to variable cargo protein sizes and membrane curvatures. The authors had also previously demonstrated that recruitment of exomer to the membrane depends on additive contributions from Arf1-GTP, which inserts into the membrane via an N-terminal amphipathic helix, and members of the ChAP family. The structure reported in this paper demonstrates that exomer interacts with Arf1-GTP via interaction surfaces on both the Chs5 and ChAP subunits. While Bch1 contacts the switch II region of Arf1 in a nucleotide-sensitive interaction reminiscent of other Arf effectors, the FBE domain of Chs5 interacts via a novel non-canonical interface near the Arf1 nucleotide binding pocket. The authors disrupt these interactions by mutating a single residue in the Arf1 exomer-binding loop and demonstrate both in vitro and in vivo that exomer is no longer recruited to membranes and that trafficking of its model cargo Chs3 is impaired. The quaternary structure of the complex, which comprises two copies of each protein, also reveals the orientation of the exomer complex with respect to the membrane. Its two Bch1 subunits and two copies of Arf1-GTP directly contact the membrane, while the hinge region of the Chs5 dimer is oriented toward the cytosol. Intriguingly, the authors show that the different ChAP family members exhibit different affinities toward membranes, with Chs5/Bch1 requiring Arf1-GTP for membrane recruitment, but Chs5/Chs6 binding independently of Arf1. A conserved basic patch on the surface of Chs6, analogous to the membrane proximal surface of Bch1, is demonstrated through mutation to be essential for membrane binding. The authors further demonstrate, through mutation of inter-subunit binding interfaces, that exomer's membrane recruitment and its trafficking function depend on its network of interactions between subunits and with the membrane. Most striking, however, is the authors' demonstration that exomer can cooperate with Arf1 to remodel membranes in vitro. They employ a vesiculation assay to monitor changes in liposome size due to vesicle fission in the presence of exomer. While Arf1 alone is shown to be capable of inducing vesiculation in the presence of GTP, the authors demonstrate that addition of Chs5/Bch1 complex dramatically strengthens this effect, with a strong preference for a TGN-like membrane composition. Addition of Chs5/Chs6 complex, however, has no such effect. Comparing the membrane binding interfaces of Bch1 and Chs6, the authors identify a hydrophobic patch on the Bch1 surface which is absent in Chs6. Mutating this hydrophobic patch to alanine has no effect on membrane recruitment of exomer, but abrogates Bch1-mediated stimulation of membrane remodeling. This suggests that the hydrophobic patch may act as a "wedge"-like membrane insertion element that cooperates with Arf1 to induce membrane curvature. The flexible hinge of the Chs5 dimer likely allows the dynamic positioning of the membrane insertion elements of both Bch1 and Arf1 during membrane remodeling to accommodate the changing curvature of the membrane. This paper offers direct evidence that the exomer complex can participate in membrane remodeling and provides crucial insights into the mechanism by which exomer, cooperating with Arf1, can induce membrane curvature. These insights hint at a broader repertoire of membrane remodeling proteins distinct from traditional coat proteins.